SLC5A2 and heart failure: The mechanisms of action of sodium-glucose cotransporter 2 (SGLT2) inhibitors in heart failure are explored, revealing their potential therapeutic benefits in enhancing cardiac function. The findings underscore the significance of SGLT2 inhibitors as a promising treatment option for heart failure, as they operate through novel mechanisms that extend beyond glycemic control and have the potential to positively influence cardiovascular outcomes